Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit By: Vor Biopharma via GlobeNewswire November 27, 2023 at 08:00 AM EST CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit. JMP Securities Hematology and Oncology SummitFireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET Location: Virtual About Vor BioVor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com. Contact: Media & InvestorsSarah Spencer +1 857-242-6076sspencer@vorbio.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit By: Vor Biopharma via GlobeNewswire November 27, 2023 at 08:00 AM EST CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit. JMP Securities Hematology and Oncology SummitFireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET Location: Virtual About Vor BioVor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com. Contact: Media & InvestorsSarah Spencer +1 857-242-6076sspencer@vorbio.com
CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit. JMP Securities Hematology and Oncology SummitFireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET Location: Virtual About Vor BioVor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com. Contact: Media & InvestorsSarah Spencer +1 857-242-6076sspencer@vorbio.com